

Guru P Sonpavde

List of Publications by Citations

Source: <https://exaly.com/author-pdf/2879158/guru-p-sonpavde-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

541
papers

11,487
citations

48
h-index

92
g-index

602
ext. papers

14,219
ext. citations

4.7
avg, IF

6.3
L-index

#	Paper	IF	Citations
541	Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. <i>Journal of the National Cancer Institute</i> , 2014 , 106, dju124	9.7	1552
540	Prostate Cancer, Version 1.2016. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016 , 14, 19-30	7.3	473
539	Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy. <i>Journal of Clinical Oncology</i> , 2011 , 29, 2432-8	2.2	349
538	Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017 , 15, 804-834	7.3	320
537	Prostate cancer, version 2.2014. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014 , 12, 686-718	7.3	261
536	Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients. <i>Cancer Immunology Research</i> , 2017 , 5, 312-318	12.5	259
535	Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology. <i>European Urology</i> , 2019 , 75, 88-99	10.2	216
534	A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. <i>Lancet Oncology</i> , 2011 , 12, 211-4	21.7	186
533	Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017 , 15, 1240-1267	7.3	172
532	A systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer. <i>European Urology</i> , 2012 , 62, 523-33	10.2	162
531	Expression of estrogen receptors-alpha and -beta in bladder cancer cell lines and human bladder tumor tissue. <i>Cancer</i> , 2006 , 106, 2610-6	6.4	160
530	Pazopanib: a novel multitargeted tyrosine kinase inhibitor. <i>Current Oncology Reports</i> , 2007 , 9, 115-9	6.3	155
529	Risk of venous thromboembolism in patients with cancer treated with Cisplatin: a systematic review and meta-analysis. <i>Journal of Clinical Oncology</i> , 2012 , 30, 4416-26	2.2	152
528	Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer. <i>Journal of Clinical Oncology</i> , 2012 , 30, 507-12	2.2	151
527	ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings. <i>European Urology</i> , 2013 , 63, 58-66	10.2	133
526	Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy. <i>Cancer</i> , 2009 , 115, 4104-9	6.4	133
525	Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma. <i>New England Journal of Medicine</i> , 2021 , 384, 1125-1135	59.2	110

524	Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium. <i>Lancet Oncology, The</i> , 2010 , 11, 861-70	21.7	105
523	The prognostic importance of metastatic site in men with metastatic castration-resistant prostate cancer. <i>European Urology</i> , 2014 , 65, 3-6	10.2	100
522	Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2012 , 30, 607-13	2.8	89
521	Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials. <i>European Urology</i> , 2013 , 63, 717-23	10.2	88
520	Optimal management of metastatic renal cell carcinoma: current status. <i>Drugs</i> , 2013 , 73, 427-38	12.1	84
519	Evolution of Circulating Tumor DNA Profile from First-line to Subsequent Therapy in Metastatic Renal Cell Carcinoma. <i>European Urology</i> , 2017 , 72, 557-564	10.2	81
518	Impact of histological variants on clinical outcomes of patients with upper urinary tract urothelial carcinoma. <i>Journal of Urology</i> , 2012 , 188, 398-404	2.5	78
517	Congestive heart failure with vascular endothelial growth factor receptor tyrosine kinase inhibitors. <i>Critical Reviews in Oncology/Hematology</i> , 2015 , 94, 228-37	7	77
516	Gemcitabine, Cisplatin, and sunitinib for metastatic urothelial carcinoma and as preoperative therapy for muscle-invasive bladder cancer. <i>Clinical Genitourinary Cancer</i> , 2013 , 11, 175-81	3.3	74
515	NCCN Guidelines Insights: Bladder Cancer, Version 2.2016. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016 , 14, 1213-1224	7.3	73
514	Detection of renal cell carcinoma using plasma and urine cell-free DNA methylomes. <i>Nature Medicine</i> , 2020 , 26, 1041-1043	50.5	72
513	Disease-free survival at 2 or 3 years correlates with 5-year overall survival of patients undergoing radical cystectomy for muscle invasive bladder cancer. <i>Journal of Urology</i> , 2011 , 185, 456-61	2.5	70
512	An open-label, single-arm, phase 2 trial of the Polo-like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer. <i>Cancer</i> , 2014 , 120, 976-82	6.4	69
511	Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma. <i>Expert Opinion on Investigational Drugs</i> , 2008 , 17, 253-61	5.9	68
510	Phase 2 Trial of Gemcitabine, Cisplatin, plus Ipilimumab in Patients with Metastatic Urothelial Cancer and Impact of DNA Damage Response Gene Mutations on Outcomes. <i>European Urology</i> , 2018 , 73, 751-759	10.2	67
509	Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2009 , 27, 391-9	2.8	66
508	Nomogram for predicting survival in patients with unresectable and/or metastatic urothelial cancer who are treated with cisplatin-based chemotherapy. <i>Cancer</i> , 2013 , 119, 3012-9	6.4	65
507	Metastatic Prostate Cancer and the Bone: Significance and Therapeutic Options. <i>European Urology</i> , 2015 , 68, 850-8	10.2	58

506	Metabolic complications with the use of mTOR inhibitors for cancer therapy. <i>Cancer Treatment Reviews</i> , 2014 , 40, 190-6	14.4	57
505	Clinical nodal staging scores for bladder cancer: a proposal for preoperative risk assessment. <i>European Urology</i> , 2012 , 61, 237-42	10.2	54
504	Novel molecular targets for the therapy of castration-resistant prostate cancer. <i>European Urology</i> , 2012 , 61, 950-60	10.2	54
503	Randomized, Noncomparative, Phase II Trial of Early Switch From Docetaxel to Cabazitaxel or Vice Versa, With Integrated Biomarker Analysis, in Men With Chemotherapy-Naïve, Metastatic, Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3181-3188	2.2	53
502	Prognostic impact of the neutrophil-to-lymphocyte ratio in men with metastatic castration-resistant prostate cancer. <i>Clinical Genitourinary Cancer</i> , 2014 , 12, 317-24	3.3	53
501	Stage pT0 at radical cystectomy confers improved survival: an international study of 4,430 patients. <i>Journal of Urology</i> , 2010 , 184, 888-94	2.5	52
500	Mutational Analysis of 472 Urothelial Carcinoma Across Grades and Anatomic Sites. <i>Clinical Cancer Research</i> , 2019 , 25, 2458-2470	12.9	52
499	Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA. <i>Cancer</i> , 2018 , 124, 2115-2124	6.4	51
498	Efficacy of selective estrogen receptor modulators in nude mice bearing human transitional cell carcinoma. <i>Urology</i> , 2007 , 69, 1221-6	1.6	51
497	Results from BLASST-1 (Bladder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in muscle invasive bladder cancer (MIBC) undergoing cystectomy.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 439-439	2.2	50
496	Venous thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis of randomized clinical trials. <i>Critical Reviews in Oncology/Hematology</i> , 2013 , 87, 80-9	7	49
495	Identification of Incidental Germline Mutations in Patients With Advanced Solid Tumors Who Underwent Cell-Free Circulating Tumor DNA Sequencing. <i>Journal of Clinical Oncology</i> , 2018 , JCO1800328	2.2	49
494	Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma 2017 , 5, 68		48
493	Single-agent Taxane Versus Taxane-containing Combination Chemotherapy as Salvage Therapy for Advanced Urothelial Carcinoma. <i>European Urology</i> , 2016 , 69, 634-641	10.2	47
492	Cisplatin and 5-fluorouracil in inoperable, stage IV squamous cell carcinoma of the penis. <i>BJU International</i> , 2012 , 110, E661-6	5.6	47
491	Epigenetics in prostate cancer. <i>Prostate Cancer</i> , 2011 , 2011, 580318	1.9	46
490	Axitinib for renal cell carcinoma. <i>Expert Opinion on Investigational Drugs</i> , 2008 , 17, 741-8	5.9	46
489	Cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy in the United States: a SEER analysis. <i>World Journal of Urology</i> , 2013 , 31, 1535-9	4	45

488	Treatment-related mortality with vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy in patients with advanced solid tumors: a meta-analysis. <i>Cancer Treatment Reviews</i> , 2012 , 38, 919-25	14.4	45
487	Sequencing of agents for metastatic renal cell carcinoma: can we customize therapy?. <i>European Urology</i> , 2012 , 61, 307-16	10.2	43
486	Lymphovascular invasion is independently associated with bladder cancer recurrence and survival in patients with final stage T1 disease and negative lymph nodes after radical cystectomy. <i>BJU International</i> , 2013 , 111, 1215-21	5.6	43
485	Administration of cisplatin-based chemotherapy for advanced urothelial carcinoma in the community. <i>Clinical Genitourinary Cancer</i> , 2012 , 10, 1-5	3.3	42
484	Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC). <i>European Urology</i> , 2017 , 71, 281-289	10.2	41
483	Treatment and Clinical Outcomes of Patients with Teratoma with Somatic-Type Malignant Transformation: An International Collaboration. <i>Journal of Urology</i> , 2016 , 196, 95-100	2.5	41
482	The activity of the androgen receptor variant AR-V7 is regulated by FOXO1 in a PTEN-PI3K-AKT-dependent way. <i>Prostate</i> , 2013 , 73, 267-77	4.2	41
481	Azacitidine favorably modulates PSA kinetics correlating with plasma DNA LINE-1 hypomethylation in men with chemonaïve castration-resistant prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2011 , 29, 682-9	2.8	41
480	Improved 5-Factor Prognostic Classification of Patients Receiving Salvage Systemic Therapy for Advanced Urothelial Carcinoma. <i>Journal of Urology</i> , 2016 , 195, 277-82	2.5	40
479	Pathologic nodal staging score for bladder cancer: a decision tool for adjuvant therapy after radical cystectomy. <i>European Urology</i> , 2013 , 63, 371-8	10.2	39
478	Modified Glasgow Prognostic Score is Associated With Risk of Recurrence in Bladder Cancer Patients After Radical Cystectomy: A Multicenter Experience. <i>Medicine (United States)</i> , 2015 , 94, e1861	1.8	39
477	The role of abiraterone acetate in the management of prostate cancer: a critical analysis of the literature. <i>European Urology</i> , 2011 , 60, 270-8	10.2	39
476	Phase II Trial of Neoadjuvant Systemic Chemotherapy Followed by Extirpative Surgery in Patients with High Grade Upper Tract Urothelial Carcinoma. <i>Journal of Urology</i> , 2020 , 203, 690-698	2.5	38
475	Validation of the AJCC TNM substaging of pT2 bladder cancer: deep muscle invasion is associated with significantly worse outcome. <i>European Urology</i> , 2010 , 58, 112-7	10.2	37
474	Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with immune checkpoint inhibitors. <i>Cancer</i> , 2020 , 126, 1208-1216	6.4	37
473	Sequencing of Cabazitaxel and Abiraterone Acetate After Docetaxel in Metastatic Castration-Resistant Prostate Cancer: Treatment Patterns and Clinical Outcomes in Multicenter Community-Based US Oncology Practices. <i>Clinical Genitourinary Cancer</i> , 2015 , 13, 309-318	3.3	36
472	Efficacy and Safety of Gemcitabine Plus Either Taxane or Carboplatin in the First-Line Setting of Metastatic Urothelial Carcinoma: A Systematic Review and Meta-Analysis. <i>Clinical Genitourinary Cancer</i> , 2017 , 15, 23-30.e2	3.3	36
471	Cisplatin-ineligible and chemotherapy-ineligible patients should be the focus of new drug development in patients with advanced bladder cancer. <i>Clinical Genitourinary Cancer</i> , 2014 , 12, 71-3	3.3	34

470	Real-World Effectiveness of Chemotherapy in Elderly Patients With Metastatic Bladder Cancer in the United States. <i>Bladder Cancer</i> , 2018 , 4, 227-238	1	33
469	Evaluating the value of number of cycles of docetaxel and prednisone in men with metastatic castration-resistant prostate cancer. <i>European Urology</i> , 2012 , 61, 363-9	10.2	32
468	Radiographic progression by Prostate Cancer Working Group (PCWG)-2 criteria as an intermediate endpoint for drug development in metastatic castration-resistant prostate cancer. <i>BJU International</i> , 2014 , 114, E25-E31	5.6	32
467	miR-34a Regulates Expression of the Stathmin-1 Oncoprotein and Prostate Cancer Progression. <i>Molecular Cancer Research</i> , 2018 , 16, 1125-1137	6.6	31
466	Prevalence and characteristics of patients with metastatic cancer who receive no anticancer therapy. <i>Cancer</i> , 2012 , 118, 5947-54	6.4	31
465	ENERGIZE: a Phase III study of neoadjuvant chemotherapy alone or with nivolumab with/without linrodostat mesylate for muscle-invasive bladder cancer. <i>Future Oncology</i> , 2020 , 16, 4359-4368	3.6	31
464	Absolute basophil count is associated with time to recurrence in patients with high-grade T1 bladder cancer receiving bacillus Calmette-Guérin after transurethral resection of the bladder tumor. <i>World Journal of Urology</i> , 2020 , 38, 143-150	4	31
463	The association between radiographic response and overall survival in men with metastatic castration-resistant prostate cancer receiving chemotherapy. <i>Cancer</i> , 2011 , 117, 3963-71	6.4	30
462	Glasgow prognostic score as a prognostic factor in metastatic castration-resistant prostate cancer treated with docetaxel-based chemotherapy. <i>Clinical Genitourinary Cancer</i> , 2013 , 11, 423-30	3.3	29
461	Ability of C-reactive protein to complement multiple prognostic classifiers in men with metastatic castration resistant prostate cancer receiving docetaxel-based chemotherapy. <i>BJU International</i> , 2012 , 110, E461-8	5.6	28
460	High Throughput Kinomic Profiling of Human Clear Cell Renal Cell Carcinoma Identifies Kinase Activity Dependent Molecular Subtypes. <i>PLoS ONE</i> , 2015 , 10, e0139267	3.7	28
459	A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinoma. <i>BJU International</i> , 2014 , 113, E137-43	5.6	28
458	GLIPR1 tumor suppressor gene expressed by adenoviral vector as neoadjuvant intraprostatic injection for localized intermediate or high-risk prostate cancer preceding radical prostatectomy. <i>Clinical Cancer Research</i> , 2011 , 17, 7174-82	12.9	28
457	New perspectives in the therapy of castration resistant prostate cancer. <i>Current Drug Targets</i> , 2012 , 13, 1676-86	3	28
456	A model combining clinical and genomic factors to predict response to PD-1/PD-L1 blockade in advanced urothelial carcinoma. <i>British Journal of Cancer</i> , 2020 , 122, 555-563	8.7	28
455	Impact of adjuvant chemotherapy in patients with adverse features and variant histology at radical cystectomy for muscle-invasive carcinoma of the bladder: Does histologic subtype matter?. <i>Cancer</i> , 2019 , 125, 1449-1458	6.4	28
454	Disease-free survival as a surrogate for overall survival in upper tract urothelial carcinoma. <i>World Journal of Urology</i> , 2013 , 31, 5-11	4	27
453	Hepatotoxicity with vascular endothelial growth factor receptor tyrosine kinase inhibitors: A meta-analysis of randomized clinical trials. <i>Critical Reviews in Oncology/Hematology</i> , 2015 , 93, 257-76	7	27

452	Clinical and pharmacokinetic evaluation of satraplatin. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2012 , 8, 103-11	5.5	27
451	Potential value of Gleason score in predicting the benefit of cabazitaxel in metastatic castration-resistant prostate cancer. <i>Future Oncology</i> , 2013 , 9, 889-97	3.6	27
450	Prognostic risk stratification of pathological stage T3N0 bladder cancer after radical cystectomy. <i>Journal of Urology</i> , 2011 , 185, 1216-21	2.5	27
449	Arterial thromboembolism in cancer patients treated with cisplatin: a systematic review and meta-analysis. <i>Journal of the National Cancer Institute</i> , 2012 , 104, 1837-40	9.7	27
448	Andrographolide inhibits prostate cancer by targeting cell cycle regulators, CXCR3 and CXCR7 chemokine receptors. <i>Cell Cycle</i> , 2016 , 15, 819-26	4.7	27
447	Type 2 diabetes mellitus predicts worse outcomes in patients with high-grade T1 bladder cancer receiving bacillus Calmette-Guérin after transurethral resection of the bladder tumor. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020 , 38, 459-464	2.8	26
446	Integrative Epigenetic and Gene Expression Analysis of Renal Tumor Progression to Metastasis. <i>Molecular Cancer Research</i> , 2019 , 17, 84-96	6.6	26
445	The hypothalamic-pituitary-gonadal axis and prostate cancer: implications for androgen deprivation therapy. <i>World Journal of Urology</i> , 2014 , 32, 669-76	4	26
444	Six-month progression-free survival as the primary endpoint to evaluate the activity of new agents as second-line therapy for advanced urothelial carcinoma. <i>Clinical Genitourinary Cancer</i> , 2014 , 12, 130-7	3.3	26
443	Concurrent chemoradiotherapy for men with locally advanced penile squamous cell carcinoma. <i>Clinical Genitourinary Cancer</i> , 2014 , 12, 440-6	3.3	26
442	Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genes. <i>Cancer</i> , 2019 , 125, 533-540	6.4	26
441	Pancreatitis with vascular endothelial growth factor receptor tyrosine kinase inhibitors. <i>Critical Reviews in Oncology/Hematology</i> , 2015 , 94, 136-45	7	25
440	Role of Chemotherapy and Mechanisms of Resistance to Chemotherapy in Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Medicine Insights: Oncology</i> , 2016 , 10, 57-66	1.8	25
439	A Role for De Novo Purine Metabolic Enzyme PAICS in Bladder Cancer Progression. <i>Neoplasia</i> , 2018 , 20, 894-904	6.4	25
438	Cytosolic phosphorylated EGFR is predictive of recurrence in early stage penile cancer patients: a retrospective study. <i>Journal of Translational Medicine</i> , 2013 , 11, 161	8.5	25
437	Prognostic risk stratification derived from individual patient level data for men with advanced penile squamous cell carcinoma receiving first-line systemic therapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014 , 32, 501-8	2.8	25
436	pT3 Substaging is a prognostic indicator for lymph node negative urothelial carcinoma of the bladder. <i>Journal of Urology</i> , 2010 , 184, 470-4	2.5	25
435	Management of recurrent testicular germ cell tumors. <i>Oncologist</i> , 2007 , 12, 51-61	5.7	25

434	Circulating tumor DNA alterations in patients with metastatic castration-resistant prostate cancer. <i>Cancer</i> , 2019 , 125, 1459-1469	6.4	25
433	Clinical Outcomes of Perioperative Chemotherapy in Patients With Locally Advanced Penile Squamous-Cell Carcinoma: Results of a Multicenter Analysis. <i>Clinical Genitourinary Cancer</i> , 2017 , 15, 548-555.e3 ²⁴	3.3	24
432	Circulating Biomarkers in Bladder Cancer. <i>Bladder Cancer</i> , 2016 , 2, 369-379	1	24
431	The role of sipuleucel-T in therapy for castration-resistant prostate cancer: a critical analysis of the literature. <i>European Urology</i> , 2012 , 61, 639-47	10.2	24
430	The double edged sword of bleeding and clotting from VEGF inhibition in renal cancer patients. <i>Current Oncology Reports</i> , 2012 , 14, 295-306	6.3	24
429	Dasatinib is preclinically active against Src-overexpressing human transitional cell carcinoma of the urothelium with activated Src signaling. <i>Molecular Cancer Therapeutics</i> , 2010 , 9, 1128-35	6.1	24
428	Diagnosis and management of urothelial carcinoma of the bladder. <i>Postgraduate Medicine</i> , 2011 , 123, 43-55	3.7	24
427	Hormone refractory prostate cancer: Management and advances. <i>Cancer Treatment Reviews</i> , 2006 , 32, 90-100	14.4	24
426	Interim fluorine-18 fluorodeoxyglucose positron emission tomography for early metabolic assessment of therapeutic response to chemotherapy for metastatic transitional cell carcinoma. <i>Clinical Genitourinary Cancer</i> , 2014 , 12, 433-9	3.3	23
425	Current preclinical models for the advancement of translational bladder cancer research. <i>Molecular Cancer Therapeutics</i> , 2013 , 12, 121-30	6.1	23
424	Association of rash with outcomes in a randomized phase II trial evaluating cetuximab in combination with mitoxantrone plus prednisone after docetaxel for metastatic castration-resistant prostate cancer. <i>Clinical Genitourinary Cancer</i> , 2012 , 10, 6-14	3.3	22
423	Peg-filgrastim and cabazitaxel in prostate cancer patients. <i>Anti-Cancer Drugs</i> , 2013 , 24, 84-9	2.4	22
422	TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1371-1382	2.2	22
421	Future directions and targeted therapies in bladder cancer. <i>Hematology/Oncology Clinics of North America</i> , 2015 , 29, 361-76, x	3.1	21
420	Mammalian SWI/SNF Complex Genomic Alterations and Immune Checkpoint Blockade in Solid Tumors. <i>Cancer Immunology Research</i> , 2020 , 8, 1075-1084	12.5	21
419	Neoadjuvant systemic therapy for urological malignancies. <i>BJU International</i> , 2010 , 106, 6-22	5.6	21
418	Corticosteroids in the management of prostate cancer: a critical review. <i>Current Treatment Options in Oncology</i> , 2015 , 16, 6	5.4	20
417	A Phase I/II Trial of BNC105P with Everolimus in Metastatic Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2015 , 21, 3420-7	12.9	20

416	Abiraterone acetate: a promising drug for the treatment of castration-resistant prostate cancer. <i>Future Oncology</i> , 2010 , 6, 665-79	3.6	20
415	Phase II trial of gemcitabine + cisplatin + ipilimumab in patients with metastatic urothelial cancer.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 357-357	2.2	20
414	Comprehensive Genomic Profiling of Upper-tract and Bladder Urothelial Carcinoma. <i>European Urology Focus</i> , 2021 , 7, 1339-1346	5.1	20
413	Five-Factor Prognostic Model for Survival of Post-Platinum Patients with Metastatic Urothelial Carcinoma Receiving PD-L1 Inhibitors. <i>Journal of Urology</i> , 2020 , 204, 1173-1179	2.5	20
412	Effect of Bleomycin Administration on the Development of Pulmonary Toxicity in Patients With Metastatic Germ Cell Tumors Receiving First-Line Chemotherapy: A Meta-Analysis of Randomized Studies. <i>Clinical Genitourinary Cancer</i> , 2017 , 15, 213-220.e5	3.3	19
411	Prognostic impact of C-reactive protein in metastatic prostate cancer: a systematic review and meta-analysis. <i>Oncology Research and Treatment</i> , 2014 , 37, 772-6	2.8	19
410	Trends in the use of cytoreductive nephrectomy in the United States. <i>Clinical Genitourinary Cancer</i> , 2012 , 10, 159-63	3.3	19
409	Prognostic risk stratification of pathological stage T2N0 bladder cancer after radical cystectomy. <i>BJU International</i> , 2011 , 108, 687-92	5.6	19
408	A validated prognostic index predicting response to dexamethasone and diethylstilbestrol in castrate-resistant prostate cancer. <i>Cancer</i> , 2010 , 116, 3595-602	6.4	19
407	Circulating Tumor DNA Alterations in Advanced Urothelial Carcinoma and Association with Clinical Outcomes: A Pilot Study. <i>European Urology Oncology</i> , 2020 , 3, 695-699	6.7	19
406	HLA-restricted NY-ESO-1 peptide immunotherapy for metastatic castration resistant prostate cancer. <i>Investigational New Drugs</i> , 2014 , 32, 235-242	4.3	18
405	Fibroblast growth factor receptors as therapeutic targets in clear-cell renal cell carcinoma. <i>Expert Opinion on Investigational Drugs</i> , 2014 , 23, 305-15	5.9	18
404	First-line systemic therapy trials for advanced transitional-cell carcinoma of the urothelium: should we stop separating cisplatin-eligible and -ineligible patients?. <i>Journal of Clinical Oncology</i> , 2010 , 28, e441-2; author reply e443-4	2.2	18
403	Systematic Review and Meta-Analysis-Is there a Benefit in Using Neoadjuvant Systemic Chemotherapy for Locally Advanced Penile Squamous Cell Carcinoma?. <i>Journal of Urology</i> , 2020 , 203, 1147-1155	2.5	18
402	Meta-analysis of regression of advanced solid tumors in patients receiving placebo or no anti-cancer therapy in prospective trials. <i>Critical Reviews in Oncology/Hematology</i> , 2016 , 98, 122-36	7	17
401	Statin use and survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide after docetaxel failure: the international retrospective observational STABEN study. <i>Oncotarget</i> , 2018 , 9, 19861-19873	3.3	17
400	Oncologic outcomes obtained after neoadjuvant and adjuvant chemotherapy for the treatment of urothelial carcinomas of the upper urinary tract: a review. <i>World Journal of Urology</i> , 2013 , 31, 77-82	4	17
399	Neutropenia as a potential pharmacodynamic marker for docetaxel-based chemotherapy in men with metastatic castration-resistant prostate cancer. <i>Clinical Genitourinary Cancer</i> , 2012 , 10, 239-45	3.3	17

398	Concomitant carcinoma in situ in cystectomy specimens is not associated with clinical outcomes after surgery. <i>Urologia Internationalis</i> , 2011 , 87, 42-8	1.9	17
397	Perioperative chemotherapy for bladder cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2006 , 57, 133-44		17
396	Prevalence of pathogenic germline cancer risk variants in high-risk urothelial carcinoma. <i>Genetics in Medicine</i> , 2020 , 22, 709-718	8.1	17
395	Apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (Borealis-2). <i>British Journal of Cancer</i> , 2018 , 118, 1434-1441	8.7	17
394	Role of Checkpoint Inhibition in Localized Bladder Cancer. <i>European Urology Oncology</i> , 2018 , 1, 190-198	6.7	17
393	Phase I trial of antigen-targeted autologous dendritic cell-based vaccine with in vivo activation of inducible CD40 for advanced prostate cancer. <i>Cancer Immunology, Immunotherapy</i> , 2017 , 66, 1345-1357	7.4	16
392	Loss of FOXP3 and TSC1 Accelerates Prostate Cancer Progression through Synergistic Transcriptional and Posttranslational Regulation of c-MYC. <i>Cancer Research</i> , 2019 , 79, 1413-1425	10.1	16
391	Urotensin II receptor on preoperative biopsy is associated with upstaging and upgrading in prostate cancer. <i>Future Oncology</i> , 2015 , 11, 3091-8	3.6	16
390	Gene Expression Profiling of Advanced Penile Squamous Cell Carcinoma Receiving Cisplatin-based Chemotherapy Improves Prognostication and Identifies Potential Therapeutic Targets. <i>European Urology Focus</i> , 2018 , 4, 733-736	5.1	16
389	Impact of response to prior chemotherapy in patients with advanced urothelial carcinoma receiving second-line therapy: implications for trial design. <i>Clinical Genitourinary Cancer</i> , 2013 , 11, 495-500	3.3	16
388	Pulmonary complications with the use of mTOR inhibitors in targeted cancer therapy: a systematic review and meta-analysis. <i>Targeted Oncology</i> , 2014 , 9, 195-204	5	16
387	Neoadjuvant chemotherapy for invasive bladder cancer. <i>Current Urology Reports</i> , 2012 , 13, 136-46	2.9	16
386	Neoadjuvant therapy followed by prostatectomy for clinically localized prostate cancer. <i>Cancer</i> , 2007 , 110, 2628-39	6.4	16
385	Combination therapy for metastatic renal cell carcinoma. <i>Annals of Translational Medicine</i> , 2016 , 4, 100	3.2	16
384	The evolving role of monoclonal antibodies in the treatment of patients with advanced renal cell carcinoma: a systematic review. <i>Expert Opinion on Biological Therapy</i> , 2016 , 16, 1387-1401	5.4	16
383	Statin Use and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Treated with Abiraterone Acetate. <i>European Urology Focus</i> , 2018 , 4, 874-879	5.1	15
382	The Impact of Adding Taxanes to Gemcitabine and Platinum Chemotherapy for the First-Line Therapy of Advanced or Metastatic Urothelial Cancer: A Systematic Review and Meta-analysis. <i>European Urology</i> , 2016 , 69, 624-633	10.2	15
381	Recent advances in immunotherapy for the treatment of prostate cancer. <i>Expert Opinion on Biological Therapy</i> , 2011 , 11, 997-1009	5.4	15

380	Bladder cancer: Angiogenesis as a therapeutic target in urothelial carcinoma. <i>Nature Reviews Urology</i> , 2016 , 13, 306-7	5.5	15
379	Cytotoxic chemotherapy in the contemporary management of metastatic castration-resistant prostate cancer (mCRPC). <i>BJU International</i> , 2015 , 116, 17-29	5.6	14
378	Precision medicine for metastatic renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014 , 32, 5-15	2.8	14
377	Residual pathological stage at radical cystectomy significantly impacts outcomes for initial T2N0 bladder cancer. <i>Journal of Urology</i> , 2009 , 182, 459-65; discussion 465	2.5	14
376	Treatment of metastatic urothelial cancer: opportunities for drug discovery and development. <i>BJU International</i> , 2008 , 102, 1354-60	5.6	14
375	Kinase Gene Expression Profiling of Metastatic Clear Cell Renal Cell Carcinoma Tissue Identifies Potential New Therapeutic Targets. <i>PLoS ONE</i> , 2016 , 11, e0160924	3.7	14
374	Prognostic and Predictive Factors in Patients with Advanced Penile Cancer Receiving Salvage (2nd or Later Line) Systemic Treatment: A Retrospective, Multi-Center Study. <i>Frontiers in Pharmacology</i> , 2016 , 7, 487	5.6	14
373	Taxane-based Combination Therapies for Metastatic Prostate Cancer. <i>European Urology Focus</i> , 2019 , 5, 369-380	5.1	14
372	Results of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignancies. <i>Cancer</i> , 2021 , 127, 840-849	6.4	14
371	Pooled Analysis of C-Reactive Protein Levels and Mortality in Prostate Cancer Patients. <i>Clinical Genitourinary Cancer</i> , 2015 , 13, e217-e221	3.3	13
370	The impact of gender on outcomes in patients with metastatic urothelial carcinoma. <i>Clinical Genitourinary Cancer</i> , 2013 , 11, 346-52	3.3	13
369	Third-Line Chemotherapy for Metastatic Urothelial Cancer: A Retrospective Observational Study. <i>Medicine (United States)</i> , 2015 , 94, e2297	1.8	13
368	Docetaxel for the treatment of bladder cancer. <i>Expert Opinion on Investigational Drugs</i> , 2015 , 24, 1657-64.9		13
367	Management of castrate resistant prostate cancer-recent advances and optimal sequence of treatments. <i>Current Urology Reports</i> , 2013 , 14, 174-83	2.9	13
366	Enzastaurin shows preclinical antitumor activity against human transitional cell carcinoma and enhances the activity of gemcitabine. <i>Molecular Cancer Therapeutics</i> , 2009 , 8, 1772-8	6.1	13
365	Abi Race: A prospective, multicenter study of black (B) and white (W) patients (pts) with metastatic castrate resistant prostate cancer (mCRPC) treated with abiraterone acetate and prednisone (AAP).. <i>Journal of Clinical Oncology</i> , 2018 , 36, LBA5009-LBA5009	2.2	13
364	Lack of Cumulative Toxicity Associated With Cabazitaxel Use in Prostate Cancer. <i>Medicine (United States)</i> , 2016 , 95, e2299	1.8	13
363	Prostate cancer cells hyper-activate CXCR6 signaling by cleaving CXCL16 to overcome effect of docetaxel. <i>Cancer Letters</i> , 2019 , 454, 1-13	9.9	12

362	Cisplatin-based first-line therapy for advanced urothelial carcinoma after previous perioperative cisplatin-based therapy. <i>Clinical Genitourinary Cancer</i> , 2015 , 13, 178-84	3.3	12
361	Taxane chemotherapy vs antiandrogen agents as first-line therapy for metastatic castration-resistant prostate cancer. <i>BJU International</i> , 2018 , 121, 871-879	5.6	12
360	Nomogram to Assess the Survival Benefit of New Salvage Agents for Metastatic Urothelial Carcinoma in the Era of Immunotherapy. <i>Clinical Genitourinary Cancer</i> , 2018 , 16, e961-e967	3.3	12
359	Impact of prednisone on toxicities and survival in metastatic castration-resistant prostate cancer: A systematic review and meta-analysis of randomized clinical trials. <i>Critical Reviews in Oncology/Hematology</i> , 2014 , 90, 253-61	7	12
358	Outcomes in patients with advanced urothelial carcinoma after discontinuation of programmed death (PD)-1 or PD ligand 1 inhibitor therapy. <i>BJU International</i> , 2017 , 119, 579-584	5.6	12
357	CD24 is a genetic modifier for risk and progression of prostate cancer. <i>Molecular Carcinogenesis</i> , 2017 , 56, 641-650	5	12
356	Activity of CEP-9722, a poly (ADP-ribose) polymerase inhibitor, in urothelial carcinoma correlates inversely with homologous recombination repair response to DNA damage. <i>Anti-Cancer Drugs</i> , 2014 , 25, 878-86	2.4	12
355	New advancements and developments in treatment of renal cell carcinoma: focus on pazopanib. <i>OncoTargets and Therapy</i> , 2010 , 3, 147-55	4.4	12
354	Cabazitaxel for the treatment of castration-resistant prostate cancer. <i>Future Oncology</i> , 2011 , 7, 15-24	3.6	12
353	SIU-ICUD recommendations on bladder cancer: systemic therapy for metastatic bladder cancer. <i>World Journal of Urology</i> , 2019 , 37, 95-105	4	12
352	Endostatin inhibits androgen-independent prostate cancer growth by suppressing nuclear receptor-mediated oxidative stress. <i>FASEB Journal</i> , 2017 , 31, 1608-1619	0.9	11
351	The effect of treatment at minority-serving hospitals on outcomes for bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018 , 36, 238.e7-238.e17	2.8	11
350	Association Between RECIST Changes and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Receiving Docetaxel. <i>European Urology</i> , 2016 , 69, 980-3	10.2	11
349	Patient eligibility and trial design for the salvage therapy of advanced urothelial carcinoma. <i>Clinical Genitourinary Cancer</i> , 2014 , 12, 395-8	3.3	11
348	Trends and variations in utilization of nephron-sparing procedures for stage I kidney cancer in the United States. <i>World Journal of Urology</i> , 2013 , 31, 1211-7	4	11
347	Efficacy of docetaxel-based chemotherapy following ketoconazole in metastatic castration-resistant prostate cancer: implications for prior therapy in clinical trials. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013 , 31, 1457-63	2.8	11
346	New approaches in hormone refractory prostate cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2006 , 29, 196-201	2.7	11
345	A phase 3, open-label, randomized study of nivolumab plus ipilimumab or standard of care (SOC) versus SOC alone in patients (pts) with previously untreated unresectable or metastatic urothelial carcinoma (mUC; CheckMate 901).. <i>Journal of Clinical Oncology</i> , 2018 , 36, TPS539-TPS539	2.2	11

344	Kinase analysis of penile squamous cell carcinoma on multiple platforms to identify potential therapeutic targets. <i>Oncotarget</i> , 2017 , 8, 21710-21718	3.3	11
343	Emerging vaccine therapy approaches for prostate cancer. <i>Reviews in Urology</i> , 2010 , 12, 25-34	1	11
342	Predictors of efficacy of androgen-receptor-axis-targeted therapies in patients with metastatic castration-sensitive prostate cancer: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2020 , 151, 102992	7	11
341	Histological Subtypes and Response to PD-1/PD-L1 Blockade in Advanced Urothelial Cancer: A Retrospective Study. <i>Journal of Urology</i> , 2020 , 204, 63-70	2.5	11
340	Incidence of Severe Nephrotoxicity With Cisplatin Based on Renal Function Eligibility Criteria: Indirect Comparison Meta-analysis. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2016 , 39, 497-506	2.7	11
339	First-line systemic therapy for metastatic castration-sensitive prostate cancer: An updated systematic review with novel findings. <i>Critical Reviews in Oncology/Hematology</i> , 2021 , 157, 103198	7	11
338	Update of systemic immunotherapy for advanced urothelial carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017 , 35, 678-686	2.8	10
337	Enfortumab Vedotin, a fully human monoclonal antibody against Nectin 4 conjugated to monomethyl auristatin E for metastatic urothelial Carcinoma. <i>Expert Opinion on Investigational Drugs</i> , 2019 , 28, 821-826	5.9	10
336	Treatment Approaches for Cisplatin-Ineligible Patients with Invasive Bladder Cancer. <i>Current Treatment Options in Oncology</i> , 2019 , 20, 12	5.4	10
335	Emerging agents for the therapy of advanced prostate cancer. <i>Future Oncology</i> , 2015 , 11, 2775-87	3.6	10
334	Cisplatin-based combination chemotherapy in septuagenarians with metastatic urothelial cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014 , 32, 30.e15-21	2.8	10
333	Critical analysis of contemporary clinical research in muscle-invasive and metastatic urothelial cancer: a report from the Bladder Cancer Advocacy Network Clinical Trials Working Group. <i>Cancer</i> , 2013 , 119, 1994-8	6.4	10
332	EV-301: Phase III study to evaluate enfortumab vedotin (EV) versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial cancer (la/mUC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, TPS497-TPS497	2.2	10
331	PGC1 β suppresses kidney cancer progression by inhibiting collagen-induced SNAIL expression. <i>Matrix Biology</i> , 2020 , 89, 43-58	11.4	10
330	Impact of the Number of Cycles of Platinum Based First Line Chemotherapy for Advanced Urothelial Carcinoma. <i>Journal of Urology</i> , 2018 , 200, 1207-1214	2.5	10
329	Conceptual Framework for Therapeutic Development Beyond Anti-PD-1/PD-L1 in Urothelial Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019 , 39, 284-300	7.1	9
328	Emerging Systemic Therapies for the Management of Penile Cancer. <i>Urologic Clinics of North America</i> , 2016 , 43, 481-491	2.9	9
327	Neoadjuvant dasatinib for muscle-invasive bladder cancer with tissue analysis of biologic activity. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016 , 34, 4.e11-7	2.8	9

326	Characterizing trends in treatment modalities for localized muscle-invasive bladder cancer in the pre-immunotherapy era. <i>World Journal of Urology</i> , 2018 , 36, 1767-1774	4	9
325	Posttreatment prognostic nomogram for patients with metastatic urothelial cancer completing first-line cisplatin-based chemotherapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014 , 32, 48.e1-8	2.8	9
324	Association of the Charlson comorbidity index and hypertension with survival in men with metastatic castration-resistant prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014 , 32, 36.e27-34	2.8	9
323	Target-specific randomized discontinuation trial design: a novel approach in molecular therapeutics. <i>Investigational New Drugs</i> , 2010 , 28, 194-8	4.3	9
322	Novel agents for muscle-invasive and advanced urothelial cancer. <i>BJU International</i> , 2008 , 101, 937-43	5.6	9
321	Phase II study of azacitidine to restore responsiveness of prostate cancer to hormonal therapy. <i>Clinical Genitourinary Cancer</i> , 2007 , 5, 457-9	3.3	9
320	Bevacizumab in renal-cell cancer. <i>New England Journal of Medicine</i> , 2003 , 349, 1674	59.2	9
319	KEYNOTE-052: Phase 2 study of pembrolizumab (MK-3475) as first-line therapy for patients (pts) with unresectable or metastatic urothelial cancer ineligible for cisplatin-based therapy.. <i>Journal of Clinical Oncology</i> , 2015 , 33, TPS4572-TPS4572	2.2	9
318	New 6-factor prognostic model for patients (pts) with advanced urothelial carcinoma (UC) receiving post-platinum atezolizumab.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 413-413	2.2	9
317	Defining platinum-ineligible patients with metastatic urothelial cancer (mUC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 451-451	2.2	9
316	A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors. <i>European Urology Oncology</i> , 2021 , 4, 464-472	6.7	9
315	Cisplatin- Versus Non-Cisplatin-based First-Line Chemotherapy for Advanced Urothelial Carcinoma Previously Treated With Perioperative Cisplatin. <i>Clinical Genitourinary Cancer</i> , 2016 , 14, 331-40	3.3	9
314	Immunotherapy of advanced renal cell carcinoma: Current and future therapies. <i>Human Vaccines and Immunotherapeutics</i> , 2016 , 12, 2997-3004	4.4	9
313	Immunotherapy for advanced penile cancer - rationale and potential. <i>Nature Reviews Urology</i> , 2018 , 15, 721-723	5.5	9
312	Immunohistochemistry to enhance prognostic allocation and guide decision-making of patients with advanced urothelial cancer receiving first-line chemotherapy. <i>Clinical Genitourinary Cancer</i> , 2015 , 13, 171-7.e1	3.3	8
311	Therapeutically actionable PAK4 is amplified, overexpressed, and involved in bladder cancer progression. <i>Oncogene</i> , 2020 , 39, 4077-4091	9.2	8
310	Conditional immune toxicity rate in patients with metastatic renal and urothelial cancer treated with immune checkpoint inhibitors 2020 , 8,		8
309	Current Staging Strategies for Muscle-Invasive Bladder Cancer and Upper Tract Urothelial Cell Carcinoma. <i>Urologic Clinics of North America</i> , 2018 , 45, 143-154	2.9	8

308	Emerging drugs for urothelial carcinoma. <i>Expert Opinion on Emerging Drugs</i> , 2013 , 18, 477-94	3.7	8
307	Suggestions for regulatory agency approval of second-line systemic therapy for metastatic transitional cell carcinoma. <i>Journal of Clinical Oncology</i> , 2010 , 28, e205-7; author reply e208	2.2	8
306	Efficacy of combined intravesical immunotherapy and chemotherapy for non-muscle invasive bladder cancer. <i>Expert Review of Anticancer Therapy</i> , 2011 , 11, 949-57	3.5	8
305	Objective measures of physical functional capacity warrant exploration to complement or replace the subjective physician estimated performance status. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2012 , 35, 163-6	2.7	8
304	Vaccine therapy for prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2007 , 25, 451-9	2.8	8
303	Patients with unusual bladder malignancies and a rare cause of splenomegaly. Case 2. Rhabdomyosarcoma of the urinary bladder in an adult. <i>Journal of Clinical Oncology</i> , 2005 , 23, 4459-60	2.2	8
302	KEYNOTE-057: Phase 2 study of pembrolizumab for patients (pts) with Bacillus Calmette Guerin (BCG)-unresponsive, high-risk non-muscle-invasive bladder cancer (NMIBC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, TPS4576-TPS4576	2.2	8
301	Circulating tumor (ct)-DNA alterations in metastatic castration-resistant prostate cancer (mCRPC): Association with outcomes and evolution with therapy.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 149-149	2.2	8
300	Alliance A031501: Phase III randomized adjuvant study of MK-3475 (pembrolizumab) in muscle-invasive and locally advanced urothelial carcinoma (MIBC) (AMBASSADOR) versus observation.. <i>Journal of Clinical Oncology</i> , 2019 , 37, TPS504-TPS504	2.2	8
299	Phase II study of nivolumab and ipilimumab for advanced rare genitourinary cancers.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 5018-5018	2.2	8
298	Kinomic profiling identifies focal adhesion kinase 1 as a therapeutic target in advanced clear cell renal cell carcinoma. <i>Oncotarget</i> , 2017 , 8, 29220-29232	3.3	8
297	Systemic treatments for metastatic urothelial carcinoma. <i>Expert Opinion on Pharmacotherapy</i> , 2019 , 20, 201-208	4	8
296	Treating Patients With Bladder Cancer: Is There an Ethical Obligation to Include Smoking Cessation Counseling?. <i>Journal of Clinical Oncology</i> , 2018 , 36, 3189-3191	2.2	8
295	Utility of cell-free nucleic acid and circulating tumor cell analyses in prostate cancer. <i>Asian Journal of Andrology</i> , 2018 , 20, 230-237	2.8	8
294	Use of Quantitative T2-Weighted and Apparent Diffusion Coefficient Texture Features of Bladder Cancer and Extravesical Fat for Local Tumor Staging After Transurethral Resection. <i>American Journal of Roentgenology</i> , 2019 , 1-10	5.4	7
293	Fatigue with vascular endothelial growth factor receptor tyrosine kinase inhibitors and mammalian target of rapamycin inhibitors in patients with renal cell carcinoma (RCC) and other malignancies: A meta-analysis of randomized clinical trials. <i>Critical Reviews in Oncology/Hematology</i> , 2015 , 95, 251-63	7	7
292	Association of tumour microRNA profiling with outcomes in patients with advanced urothelial carcinoma receiving first-line platinum-based chemotherapy. <i>British Journal of Cancer</i> , 2016 , 115, 12-9	8.7	7
291	Expression and Role of Methylenetetrahydrofolate Dehydrogenase 1 Like (MTHFD1L) in Bladder Cancer. <i>Translational Oncology</i> , 2019 , 12, 1416-1424	4.9	7

290	Contemporary management of metastatic castration-resistant prostate cancer. <i>Current Opinion in Urology</i> , 2011 , 21, 241-7	2.8	7
289	The role of docetaxel based therapy for prostate cancer in the era of targeted medicine. <i>International Journal of Urology</i> , 2010 , 17, 228-40	2.3	7
288	Satraplatin for the therapy of castration-resistant prostate cancer. <i>Future Oncology</i> , 2009 , 5, 931-40	3.6	7
287	Lapatinib plus capecitabine in breast cancer. <i>New England Journal of Medicine</i> , 2007 , 356, 1471; author reply 1471-2	59.2	7
286	Communicating the value of adjuvant chemotherapy. <i>Journal of Clinical Oncology</i> , 2003 , 21, 948-9	2.2	7
285	A phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) in combination with axitinib in patients with metastatic renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 426-426	2.2	7
284	Examining the relationship between complications and perioperative mortality following radical cystectomy: a population-based analysis. <i>BJU International</i> , 2019 , 124, 40-46	5.6	7
283	Predictive Role of Computed Tomography Texture Analysis in Patients with Metastatic Urothelial Cancer Treated with Programmed Death-1 and Programmed Death-ligand 1 Inhibitors. <i>European Urology Oncology</i> , 2020 , 3, 680-686	6.7	7
282	The cost effectiveness of pembrolizumab versus chemotherapy or atezolizumab as second-line therapy for advanced urothelial carcinoma in the United States. <i>Journal of Medical Economics</i> , 2020 , 23, 967-977	2.4	6
281	Robot-assisted Versus Open Radical Cystectomy in Patients Receiving Perioperative Chemotherapy for Muscle-invasive Bladder Cancer: The Oncologist's Perspective from a Multicentre Study. <i>European Urology Focus</i> , 2018 , 4, 937-945	5.1	6
280	Chemotherapy for Muscle-Invasive Bladder Cancer: Better Late Than Never?. <i>Journal of Clinical Oncology</i> , 2016 , 34, 780-5	2.2	6
279	Tivozanib for the treatment of renal cell carcinoma: results and implications of the TIVO-1 trial. <i>Future Oncology</i> , 2014 , 10, 1819-26	3.6	6
278	Update in systemic therapy of urologic malignancies. <i>Postgraduate Medicine</i> , 2014 , 126, 44-54	3.7	6
277	Immunotherapy for castration-resistant prostate cancer. <i>Urologic Clinics of North America</i> , 2012 , 39, 465-471	3.1	6
276	Relationship between 6- and 9-month progression-free survival and overall survival in patients with metastatic urothelial cancer treated with first-line cisplatin-based chemotherapy. <i>Cancer</i> , 2013 , 119, 3020-6	6.4	6
275	Phase II trial of sunitinib for the therapy of progressive metastatic castration-refractory prostate cancer after previous docetaxel chemotherapy. <i>Clinical Genitourinary Cancer</i> , 2008 , 6, 134-7	3.3	6
274	Recent advances in the therapy of renal cancer. <i>Expert Opinion on Biological Therapy</i> , 2007 , 7, 233-42	5.4	6
273	KEYNOTE-045: Randomized phase 3 trial of pembrolizumab (MK-3475) versus paclitaxel, docetaxel, or vinflunine for previously treated metastatic urothelial cancer.. <i>Journal of Clinical Oncology</i> , 2015 , 33, TPS4571-TPS4571	2.2	6

272	Impact of concurrent medications on outcomes with PD1/PD-L1 inhibitors for metastatic urothelial carcinoma.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 435-435	2.2	6
271	Durvalumab as neoadjuvant therapy for muscle-invasive bladder cancer: Preliminary results from the Bladder Cancer Signal Seeking Trial (BLASST)-2.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 507-507	2.2	6
270	Alterations and Response to Immunotherapy in Solid Tumors. <i>Clinical Cancer Research</i> , 2021 , 27, 4025-4035	2.2	6
269	Immune-related adverse events with PD-1 versus PD-L1 inhibitors: a meta-analysis of 8730 patients from clinical trials. <i>Future Oncology</i> , 2021 , 17, 2545-2558	3.6	6
268	Renal toxicity with mammalian target of rapamycin inhibitors: A meta-analysis of randomized clinical trials. <i>Oncology Reviews</i> , 2019 , 13, 455	4.3	6
267	Impact of tumor, treatment, and access on outcomes in bladder cancer: Can equal access overcome race-based differences in survival?. <i>Cancer</i> , 2019 , 125, 1319-1329	6.4	6
266	Cabozantinib for Progressive Metastatic Castration-resistant Prostate Cancer Following Docetaxel: Combined Analysis of Two Phase 3 Trials. <i>European Urology Oncology</i> , 2020 , 3, 540-543	6.7	6
265	Drug development in prostate cancer: time to embrace RECIST?. <i>Lancet Oncology, The</i> , 2017 , 18, 419-421	2.7	5
264	Effect of African-American Race on Tumor Recurrence After Radical Cystectomy for Urothelial Carcinoma of the Bladder. <i>Clinical Genitourinary Cancer</i> , 2015 , 13, 469-75	3.3	5
263	Incomplete Cross-Resistance Between Taxanes for Advanced Urothelial Carcinoma: Implications for Clinical Practice and Trial Design. <i>Clinical Genitourinary Cancer</i> , 2015 , 13, 250-6	3.3	5
262	Combination of cyclin-dependent kinase and immune checkpoint inhibitors for the treatment of bladder cancer. <i>Cancer Immunology, Immunotherapy</i> , 2020 , 69, 2305-2317	7.4	5
261	Overview of Current and Future Adjuvant Therapy for High-Risk Localized Renal Cell Carcinoma. <i>Current Treatment Options in Oncology</i> , 2018 , 19, 2	5.4	5
260	A new approach to second-line therapy for urothelial cancer?. <i>Lancet Oncology, The</i> , 2013 , 14, 682-4	21.7	5
259	The biology of prostate cancer metastases: does oligo differ from polymetastatic?. <i>Current Opinion in Urology</i> , 2017 , 27, 542-546	2.8	5
258	Neoadjuvant therapy preceding prostatectomy for prostate cancer: rationale and current trials. <i>Expert Review of Anticancer Therapy</i> , 2010 , 10, 439-50	3.5	5
257	Hypomethylating agents for urologic cancers. <i>Future Oncology</i> , 2011 , 7, 447-63	3.6	5
256	Patient selection for phase II trials. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2009 , 32, 216-9	2.7	5
255	Current optimal chemotherapy for advanced urothelial cancer. <i>Expert Review of Anticancer Therapy</i> , 2008 , 8, 51-61	3.5	5

254	Post-treatment prognostic model for patients (pts) with metastatic urothelial cancer (UC) treated with first-line chemotherapy.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 256-256	2.2	5
253	A phase 3, open-label, randomized study of nivolumab plus ipilimumab or standard of care (SoC) vs SoC alone in patients (pts) with previously untreated unresectable or metastatic urothelial carcinoma (mUC; CheckMate 901).. <i>Journal of Clinical Oncology</i> , 2018 , 36, TPS4588-TPS4588	2.2	5
252	Contemporary molecular tests for prognosis and treatment guidance for castration-resistant prostate cancer. <i>Expert Review of Molecular Diagnostics</i> , 2016 , 16, 1113-1120	3.8	5
251	Primary results of EV-301: A phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial carcinoma.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 393-393	2.2	5
250	CDH1 germline variants are enriched in patients with colorectal cancer, gastric cancer, and breast cancer.. <i>British Journal of Cancer</i> , 2021 ,	8.7	5
249	Salvage systemic therapy for advanced urothelial carcinoma: on the cusp of a sea change?. <i>Oncologist</i> , 2015 , 20, 461-3	5.7	4
248	Nomogram to predict the benefit from salvage systemic therapy for advanced urothelial carcinoma. <i>BJU International</i> , 2015 , 115, 854-5	5.6	4
247	Danger on a half shell: <i>Vibrio vulnificus</i> septicemia. <i>American Journal of Medicine</i> , 2015 , 128, 475-6	2.4	4
246	Neoadjuvant therapy for muscle-invasive bladder cancer. <i>Expert Review of Anticancer Therapy</i> , 2020 , 20, 603-614	3.5	4
245	The Influence of Prednisone on the Efficacy of Cabazitaxel in Men with Metastatic Castration-Resistant Prostate Cancer. <i>Journal of Cancer</i> , 2017 , 8, 2663-2668	4.5	4
244	Effect of Single-agent Daily Prednisone on Outcomes and Toxicities in Metastatic Castration-resistant Prostate Cancer: Pooled Analysis of Prospective Studies. <i>Clinical Genitourinary Cancer</i> , 2018 , 16, e277-e287	3.3	4
243	The prospects for combination therapy with capecitabine in the rapidly evolving treatment landscape of renal cell carcinoma. <i>Expert Opinion on Investigational Drugs</i> , 2018 , 27, 163-170	5.9	4
242	Immunotherapy for Renal Cancer: Sequencing and Combinations. <i>European Urology Focus</i> , 2016 , 2, 582-588	3.8	4
241	Pooled analysis of phase II trials evaluating weekly or conventional cisplatin as first-line therapy for advanced urothelial carcinoma. <i>Clinical Genitourinary Cancer</i> , 2013 , 11, 316-20	3.3	4
240	Problems with the randomized discontinuation design. <i>Journal of Clinical Oncology</i> , 2006 , 24, 4669-70; author reply 4670-1	2.2	4
239	Targeting growth factor and antiangiogenic pathways in clear-cell renal cell carcinoma: rationale and ongoing trials. <i>Clinical Genitourinary Cancer</i> , 2006 , 5 Suppl 1, S31-9	3.3	4
238	What to do when you discover testicular cancer. Helping patients overcome fear and choose treatment. <i>Postgraduate Medicine</i> , 1999 , 105, 229-36	3.7	4
237	Prognostic model for overall survival in patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 4524-4524	2.2	4

236	Biologic activity of dasatinib administered as neoadjuvant therapy preceding radical cystectomy (RC) for muscle-invasive bladder cancer (MIBC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 324-324	2.2	4
235	A phase 2 study of the histone deacetylase (HDAC) inhibitor mocetinostat in patients with urothelial carcinoma (UC) and inactivating alterations of acetyltransferase genes.. <i>Journal of Clinical Oncology</i> , 2015 , 33, TPS4575-TPS4575	2.2	4
234	Circulating cell-free DNA profiling of patients with advanced urothelial carcinoma of the bladder.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 4528-4528	2.2	4
233	Anti-tumor activity, safety and pharmacokinetics (PK) of AGS15E (ASG-15ME) in a phase I dose escalation trial in patients (Pts) with metastatic urothelial cancer (mUC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 4532-4532	2.2	4
232	Circulating cell-free DNA profiling of patients with advanced urothelial carcinoma.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 358-358	2.2	4
231	PROOF 302: A randomized, double-blind, placebo-controlled, phase III trial of infigratinib as adjuvant therapy in patients with invasive urothelial carcinoma harboring susceptible FGFR3 alterations.. <i>Journal of Clinical Oncology</i> , 2020 , 38, TPS5095-TPS5095	2.2	4
230	The emerging landscape of germline variants in urothelial carcinoma: Implications for genetic testing. <i>Cancer Treatment and Research Communications</i> , 2020 , 23, 100165	2	4
229	Rare Genitourinary Malignancies: Current Status and Future Directions of Immunotherapy. <i>European Urology Focus</i> , 2020 , 6, 14-16	5.1	4
228	Obesity and Outcomes in Patients with Metastatic Urothelial Carcinoma. <i>Bladder Cancer</i> , 2016 , 2, 341-349		4
227	Quantifying the Overall Survival Benefit With Early Radical Cystectomy for Patients With Histologically Confirmed T1 Non-muscle-invasive Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2020 , 18, e651-e659	3.3	4
226	Clinical Outcomes of Platinum-ineligible Patients with Advanced Urothelial Carcinoma Treated With First-line PD1/L1 Inhibitors. <i>Clinical Genitourinary Cancer</i> , 2021 , 19, 425-433	3.3	4
225	The angiopoietin-TIE2 pathway is a potential therapeutic target in urothelial carcinoma. <i>Anticancer Research</i> , 2014 , 34, 3377-82	2.3	4
224	A global approach to improving penile cancer care.. <i>Nature Reviews Urology</i> , 2021 ,	5.5	4
223	Validation of the Association of RECIST Changes With Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated on SWOG Study S0421. <i>Clinical Genitourinary Cancer</i> , 2017 , 15, 635-641	3.3	3
222	Prevalence of Measurable Disease in Metastatic Castration-resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2017 , 15, 534-539	3.3	3
221	Muscle-invasive Urothelial Cancer: Association of Mutational Status with Metastatic Pattern and Survival. <i>Radiology</i> , 2020 , 295, 572-580	20.5	3
220	A CD24-p53 axis contributes to African American prostate cancer disparities. <i>Prostate</i> , 2020 , 80, 609-618	4.2	3
219	Advanced urothelial cancer: a radiology update. <i>Abdominal Radiology</i> , 2019 , 44, 3858-3873	3	3

218	Novel antiangiogenic agents in the treatment of refractory renal cell carcinoma. <i>Clinical Genitourinary Cancer</i> , 2008 , 6 Suppl 1, S29-36	3.3	3
217	Phase II study of gemcitabine, cisplatin, and sunitinib (S) in patients with advanced urothelial carcinoma (UC).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 282-282	2.2	3
216	The Borealis-2 clinical trial: A randomized phase 2 study of OGX-427 (apatorsen) plus docetaxel versus docetaxel alone in relapsed/refractory metastatic urothelial cancer.. <i>Journal of Clinical Oncology</i> , 2014 , 32, TPS4593-TPS4593	2.2	3
215	Evaluation of basal and luminal subtypes of urothelial carcinoma in African American and non-African American patients.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 305-305	2.2	3
214	Adjuvant versus neoadjuvant chemotherapy for muscle-invasive bladder cancer (MIBC): Analysis of the National Cancer Database (NCDB).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 4524-4524	2.2	3
213	TAXYENERGY: Randomized trial of early switch from first-line docetaxel (D) to cabazitaxel (C) or vice versa with circulating tumor cell (CTC) biomarkers in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 5007-5007	2.2	3
212	Phase I trial of ALT-801, a first-in-class T-cell receptor (TCR)-interleukin (IL)-2 fusion molecule, plus gemcitabine (G) for Bacillus Calmette Guerin (BCG)-resistant non-muscle-invasive bladder cancer (NMIBC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 451-451	2.2	3
211	5-factor prognostic model for survival of patients with metastatic urothelial carcinoma receiving three different post-platinum PD-L1 inhibitors.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 4552-4552	2.2	3
210	Impact of pure versus mixed metastatic urothelial carcinoma (mUC) histology on response with immune checkpoint inhibitors (ICIs).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 479-479	2.2	3
209	Safety and efficacy of immune checkpoint inhibitors (CPI) in metastatic renal cell cancer (RCC) and urothelial cancer (UC) patients (pts) with pre-existing autoimmune disorders (AD).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 653-653	2.2	3
208	Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes. <i>BJU International</i> , 2021 , 128, 196-205	5.6	3
207	Trans-ethnic variation in germline variants of patients with renal cell carcinoma. <i>Cell Reports</i> , 2021 , 34, 108926	10.6	3
206	Promising immunotherapy for prostate cancer. <i>Expert Opinion on Biological Therapy</i> , 2018 , 18, 109-120	5.4	3
205	The preclinical activity of lenalidomide in indolent urothelial carcinoma. <i>Anticancer Research</i> , 2014 , 34, 3383-9	2.3	3
204	Complete response as an intermediate end point in patients receiving salvage systemic therapy for urothelial carcinoma. <i>Clinical Genitourinary Cancer</i> , 2015 , 13, 185-92	3.3	2
203	Intracranial meningeal carcinomatosis in metastatic castration resistant prostate cancer: will extension of survival increase the incidence?. <i>Clinical Genitourinary Cancer</i> , 2012 , 10, 271-3	3.3	2
202	Systemic therapy and novel agents for metastatic castration resistant prostate cancer. <i>Update on Cancer Therapeutics</i> , 2009 , 3, 133-145		2
201	Neoadjuvant chemotherapy preceding cystectomy for bladder cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2008 , 9, 1885-93	4	2

200	Frequency of cisplatin administration in patients presenting with advanced urothelial carcinoma in the community.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 285-285	2.2	2
199	Impact of baseline prognostic factors on progression-free survival at 6 months (PFS6) and response in patients receiving second-line therapy for advanced urothelial carcinoma (UC).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 301-301	2.2	2
198	Sequencing of cabazitaxel and abiraterone acetate following docetaxel in metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 79-79	2.2	2
197	Trends in neoadjuvant chemotherapy (NAC) use for muscle-invasive bladder cancer (MIBC): An updated report using the National Cancer Database (NCDB).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 4540-4540 ^{2,2}	2.2	2
196	Identification of putative germline mutations in 10,288 patients undergoing circulating tumor DNA testing.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1514-1514	2.2	2
195	Circulating tumor (ct)-DNA alterations in urothelial/bladder cancer (UC/BC): Updates on a dynamic genomic landscape.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 4534-4534	2.2	2
194	Cabozantinib for metastatic castration-resistant prostate cancer (mCRPC) following docetaxel: Combined analysis of two phase III trials.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 225-225	2.2	2
193	Innovative systemic therapies for penile cancer. <i>Current Opinion in Urology</i> , 2022 , 32, 8-16	2.8	2
192	Radium-223 (Rad) and niraparib (Nira) treatment (tx) in castrate-resistant prostate cancer (CRPC) patients (pts) with and without prior chemotherapy (chemo).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 5540-5540 ^{2,2}	2.2	2
191	JAVELIN: avelumab another spear to fight urothelial carcinoma. <i>Lancet Oncology, The</i> , 2018 , 19, 5-7	21.7	2
190	Central Nervous System Metastasis in Patients With Urothelial Carcinoma: Institutional Experience and a Comprehensive Review of the Literature. <i>Clinical Genitourinary Cancer</i> , 2020 , 18, e266-e276	3.3	2
189	New Insights into the Molecular Profile of Penile Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2021 , 27, 2375-2377	12.9	2
188	Angiotensin Blockade Modulates the Activity of PD1/L1 Inhibitors in Metastatic Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2021 ,	3.3	2
187	Optimal pathological response after neoadjuvant chemotherapy for muscle-invasive bladder cancer: results from a global, multicentre collaboration. <i>BJU International</i> , 2021 , 128, 607-614	5.6	2
186	Spectrum of FGFR2/3 Alterations in Cell-Free DNA of Patients with Advanced Urothelial Carcinoma. <i>Bladder Cancer</i> , 2021 , 7, 143-148	1	2
185	Vaccine therapy in renal cell carcinoma: attempting to leap over a rising bar. <i>Lancet Oncology, The</i> , 2016 , 17, 1477-1478	21.7	2
184	Salvage systemic therapy for metastatic urothelial carcinoma: an unmet clinical need. <i>Expert Review of Anticancer Therapy</i> , 2021 , 21, 299-313	3.5	2
183	CDKN2A alterations as markers of immune checkpoint blockade (ICB) resistance in urothelial carcinoma (UC).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 475-475	2.2	2

182	RAF1 amplification drives a subset of bladder tumors and confers sensitivity to MAPK-directed therapeutics. <i>Journal of Clinical Investigation</i> , 2021 , 131,	15.9	2
181	Neoadjuvant chemotherapy for bladder cancer. <i>Oncology</i> , 2007 , 21, 1673-81; discussion 1686-8, 1691, 1694	1.8	2
180	Integration of Bone and Computed Tomography Scans to Assess Bone Metastasis in Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2017 , 15, 53-59	3.3	1
179	From the Uncertainties to the Evidence: A Brief History of Immunotherapy as Salvage Therapy for Advanced Bladder Cancer Through a Meta-analysis. <i>Clinical Genitourinary Cancer</i> , 2017 , 15, 509-512.e9	3.3	1
178	PSA declines and survival in patients with metastatic castration-resistant prostate cancer treated with enzalutamide: A retrospective case-report study. <i>Medicine (United States)</i> , 2017 , 96, e6817	1.8	1
177	The expanding role of chemotherapy in prostate cancer. <i>Future Oncology</i> , 2015 , 11, 2637-2640	3.6	1
176	Can RECIST response predict success in phase 3 trials in men with metastatic castration-resistant prostate cancer?. <i>Prostate Cancer and Prostatic Diseases</i> , 2018 , 21, 419-430	6.2	1
175	Prognosis of renal-cell carcinoma: recognising host genetics. <i>Lancet Oncology, The</i> , 2013 , 14, 9-10	21.7	1
174	Novel molecular targets for the therapy of urothelial carcinoma. <i>Expert Opinion on Therapeutic Targets</i> , 2012 , 16, 499-513	6.4	1
173	Abiraterone acetate for metastatic prostate cancer. <i>Lancet Oncology, The</i> , 2012 , 13, 958-9	21.7	1
172	A conventional preclinical schedule of cisplatin is more effective than a metronomic frequent bolus schedule for urothelial carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013 , 31, 234-40	2.8	1
171	Trial design for metastatic castration-resistant prostate cancer. <i>Journal of Clinical Oncology</i> , 2008 , 26, 3647-8; author reply 3648-9	2.2	1
170	Systemic chemotherapy for urothelial cancer. <i>Clinical Genitourinary Cancer</i> , 2006 , 5, 34-42	3.3	1
169	PSA and clinical responses to celecoxib in a patient with prostate cancer and bone metastases. <i>Mayo Clinic Proceedings</i> , 2005 , 80, 1100-1	6.4	1
168	Serial ctDNA analysis predicts clinical progression in patients with advanced urothelial carcinoma.. <i>British Journal of Cancer</i> , 2022 ,	8.7	1
167	Correlation of progression-free survival at 6 months (PFS6) with overall survival at 12 months (OS12) in an analysis of 10 trials of second-line therapy for advanced urothelial carcinoma (UC).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 4525-4525	2.2	1
166	Trends in the use of cytoreductive nephrectomy for metastatic renal cell carcinoma in the VEGFR tyrosine kinase inhibitor era.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 4623-4623	2.2	1
165	Prognostic stratification of post-docetaxel metastatic castration resistant prostate cancer (mCRPC) from a phase III randomized trial.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 4644-4644	2.2	1

164	Phase II trial of tamoxifen for progressive advanced urothelial carcinoma following prior chemotherapy.. <i>Journal of Clinical Oncology</i> , 2012 , 30, e15003-e15003	2.2	1
163	Randomized phase II study of docetaxel with or without ramucirumab (IMC-1121B) or icrucumab (IMC-18F1) in patients with urothelial transitional cell carcinoma (TCC) following progression on first-line platinum-based therapy.. <i>Journal of Clinical Oncology</i> , 2012 , 30, TPS4675-TPS4675	2.2	1
162	Proportion of elderly patients with advanced bladder cancer receiving cisplatin-based chemotherapy: A large Medicare database study.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 276-276	2.2	1
161	Metabolic complications with the use of mTOR inhibitors for cancer therapy: A systematic review and meta-analysis.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 398-398	2.2	1
160	Impact of number of lines of therapy following docetaxel (D) in metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 223-223	2.2	1
159	Impact of prior platinum agent and site of primary in patients with advanced urothelial carcinoma (UC) receiving salvage therapy.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 336-336	2.2	1
158	Impact of number of lines of prior chemotherapy in patients (pts) with advanced urothelial carcinoma (UC) receiving salvage therapy.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 353-353	2.2	1
157	Distribution and geographic accessibility of prostate cancer clinical trials in the United States.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 59-59	2.2	1
156	Improved prognostic classification of patients receiving salvage systemic therapy for advanced urothelial carcinoma.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 311-311	2.2	1
155	Integration of bone scan (BS) and computerized tomography (CT) findings as an endpoint to assess bone metastasis in metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 191-191	2.2	1
154	The prevalence of objectively measurable disease in phase III trials of metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 215-215	2.2	1
153	Outcomes of advanced urothelial carcinoma following discontinuation of programmed death (PD)-1 or PD-ligand (L)-1 inhibitors.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 385-385	2.2	1
152	Whole-exome sequencing (WES) of penile squamous cell carcinoma (PSCC) to identify multiple recurrent mutations.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 484-484	2.2	1
151	Nomogram to assess benefit of new over historical agents as salvage therapy for metastatic urothelial carcinoma (mUC) in non-randomized trials: Effect of atezolizumab on 12-month survival.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 346-346	2.2	1
150	Nivolumab demonstrates benefit over nomogram-predicted 12-month survival as salvage therapy for metastatic urothelial carcinoma.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 451-451	2.2	1
149	A phase 3b safety study of fixed-dose durvalumab + tremelimumab or durvalumab monotherapy in advanced solid malignancies (STRONG): Urothelial and non-urothelial urinary tract carcinoma module A.. <i>Journal of Clinical Oncology</i> , 2018 , 36, TPS538-TPS538	2.2	1
148	First-line PD1/PD-L1 inhibitors for platinum-ineligible advanced urothelial carcinoma (UC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 432-432	2.2	1
147	PD-L1 and p16 expression in penile squamous cell carcinoma from an endemic region.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 515-515	2.2	1

146	Any regression of tumor (ART) within 12 weeks versus RECIST 1.1 response category as an intermediate endpoint to assess the activity of immune checkpoint inhibitors (ICIs) for metastatic urothelial carcinoma (mUC).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 473-473	2.2	1
145	FGFR2/3 genomic alterations and response to Enfortumab Vedotin in metastatic urothelial carcinoma.. <i>BJUI Compass</i> , 2022 , 3, 169-172	0.9	1
144	Multiplatform comprehensive kinase analysis of penile squamous cell carcinoma (PSCC) to identify drivers and potentially actionable therapeutic targets.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 389-389	2.2	1
143	Incidence and risk of infections in renal cell cancer (RCC) and non-RCC patients treated with everolimus and tamsirolimus: A meta-analysis of randomized control trials.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 353-353	2.2	1
142	Quality of life, functioning, and symptoms in patients with previously treated locally advanced or metastatic urothelial carcinoma from EV-301: A randomized phase 3 trial of enfortumab vedotin versus chemotherapy.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 4539-4539	2.2	1
141	Biomarker analysis of phase (Ph) IB trial of radium-223 (Rad) and niraparib (Nira) in patients (Pts) with metastatic castrate-resistant prostate cancer (mCRPC) (NiraRad).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 5036-5036	2.2	1
140	Preclinical Models for Bladder Cancer Research. <i>Hematology/Oncology Clinics of North America</i> , 2021 , 35, 613-632	3.1	1
139	Re: Immediate Versus Deferred Chemotherapy After Radical Cystectomy in Patients with pT3-pT4 or N+ M0 Urothelial Carcinoma of the Bladder (EORTC 30994): An Intergroup, Open-label, Randomised Phase 3 Trial. <i>European Urology</i> , 2016 , 70, 203	10.2	1
138	ARID1A-mutant and deficient bladder cancer is sensitive to EZH2 pharmacologic inhibition		1
137	Sequencing of PD-1/L1 Inhibitors and Carboplatin Based Chemotherapy for Cisplatin Ineligible Metastatic Urothelial Carcinoma. <i>Journal of Urology</i> , 2021 , 205, 414-419	2.5	1
136	Efficacy of enfortumab vedotin in advanced urothelial cancer: Retrospective analysis of the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) Study.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 443-443	2.2	1
135	Impact of FGFR2/3 activating genomic alterations on response to enfortumab vedotin in metastatic urothelial carcinoma (mUC).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 472-472	2.2	1
134	Impact of angiotensin blockade on response to PD1/L1 inhibitors for patients with metastatic urothelial carcinoma (mUC).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 453-453	2.2	1
133	Genomic landscape of variant urinary tumor histologies.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 467-467	2.2	1
132	Enrichment of FGFR3-TACC3 Fusions in Patients With Bladder Cancer Who Are Young, Asian, or Have Never Smoked. <i>JCO Precision Oncology</i> , 2018 , 2,	3.6	1
131	Outcomes of metastatic urothelial carcinoma following discontinuation of enfortumab-vedotin. <i>Clinical Genitourinary Cancer</i> , 2021 ,	3.3	1
130	Clinical characterization of radiation-associated muscle-invasive bladder cancer. <i>Urology</i> , 2021 , 154, 208-214	2.4	1
129	Real-world burden of illness and unmet need in locally advanced or metastatic urothelial carcinoma following discontinuation of PD-1/L1 inhibitor therapy: A Medicare claims database analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021 , 39, 733.e1-733.e10	2.8	1

128	Randomized phase II trial of gemcitabine, avelumab and carboplatin versus no neoadjuvant therapy preceding surgery for cisplatin-ineligible muscle-invasive urothelial carcinoma (MIUC): SWOG GAP trial (S2011).. <i>Journal of Clinical Oncology</i> , 2022 , 40, TPS591-TPS591	2.2	1
127	Therapy for Muscle-Invasive Urothelial Carcinoma: Controversies and Dilemmas.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2102928	2.2	1
126	Response and Outcomes to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer Based on Prior Intravesical Bacillus Calmette-Guerin.. <i>Clinical Genitourinary Cancer</i> , 2021 ,	3.3	1
125	Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study. <i>Cancer</i> , 2021 ,	6.4	1
124	Enfortumab vedotin-ejfv for the treatment of advanced urothelial carcinoma.. <i>Expert Review of Anticancer Therapy</i> , 2022 ,	3.5	1
123	Primary results of STRONG: An open-label, multicenter, phase 3b study of fixed-dose durvalumab monotherapy in previously treated patients with urinary tract carcinoma.. <i>European Journal of Cancer</i> , 2022 , 163, 55-65	7.5	0
122	Profiling of circulating tumor (ct)-DNA for potentially actionable targets in prostate cancer (PCa).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 5035-5035	2.2	0
121	Association of circulating tumor DNA (ctDNA) detection in metastatic renal cell carcinoma (mRCC) with tumor burden.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 4582-4582	2.2	0
120	Serial ctDNA tracking reveals clonal evolution dynamics in advanced urothelial carcinoma (UC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 401-401	2.2	0
119	A phase III randomized study of neoadjuvant chemotherapy (NAC) alone or in combination with nivolumab (NIVO) ± linrodostat mesylate, followed by adjuvant postsurgical NIVO ± linrodostat, in cisplatin-eligible muscle invasive bladder cancer (MIBC).. <i>Journal of Clinical Oncology</i> , 2020 , 38, TPS5091-TPS5091	2.2	0
118	Identification of actionable BRAF mutations and their genomic associations in advanced prostate cancer.. <i>Journal of Clinical Oncology</i> , 2020 , 38, e17597-e17597	2.2	0
117	Efficacy of anti-PD(L)1 therapy for patients (Pts) with advanced urothelial carcinoma (aUC) with primary resistance to platinum-based chemotherapy (PC).. <i>Journal of Clinical Oncology</i> , 2021 , 39, e16515-e16515	2.2	0
116	Gene Expression Signature Correlates with Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with Everolimus Alone or with a Vascular Disrupting Agent. <i>Molecular Cancer Therapeutics</i> , 2021 , 20, 1454-1461	6.1	0
115	Association between sites of metastases (mets) and outcomes with immune checkpoint inhibitor (ICI) therapy for advanced urothelial carcinoma (aUC).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 445-445	2.2	0
114	Treatment patterns among patients with advanced urothelial carcinoma following discontinuation of PD1/L1 inhibitor therapy.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 414-414	2.2	0
113	Early changes in peripheral blood neutrophil-lymphocyte ratio (NLR) to predict outcomes with immune checkpoint inhibitors (ICIs) for metastatic urothelial carcinoma (mUC).. <i>Journal of Clinical Oncology</i> , 2022 , 40, 449-449	2.2	0
112	Biomarker analysis and updated clinical follow-up from BLASST-1 (Bladder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in patients with muscle-invasive bladder cancer (MIBC) undergoing cystectomy.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 528-528	2.2	0
111	Sacituzumab govitecan (SG) plus enfortumab vedotin (EV) for metastatic urothelial carcinoma (UC) progressing on platinum-based chemotherapy and PD1/L1 inhibitors (ICB): Double antibody drug conjugate (DAD) phase I trial.. <i>Journal of Clinical Oncology</i> , 2022 , 40, TPS588-TPS588	2.2	0

110	Comprehensive metabolomic profiling of plasma from patients (pts) with metastatic urothelial carcinoma (mUC) receiving immune checkpoint inhibitors (ICI) or platinum-based chemotherapy (PBC).. <i>Journal of Clinical Oncology</i> , 2022 , 40, 565-565	2.2	0
109	Phase Ib trial of erdafitinib (E) combined with enfortumab vedotin (EV) following platinum and PD-1/L1 inhibitors for metastatic urothelial carcinoma (mUC) with FGFR2/3 genetic alterations (GAs).. <i>Journal of Clinical Oncology</i> , 2022 , 40, TPS595-TPS595	2.2	0
108	Association of changes in albumin levels with survival and toxicities in patients (pts) with metastatic urothelial carcinoma (mUC) receiving enfortumab vedotin (EV).. <i>Journal of Clinical Oncology</i> , 2022 , 40, 481-481	2.2	0
107	Futibatinib plus pembrolizumab in patients (pts) with advanced or metastatic urothelial carcinoma (mUC): Preliminary safety results from a phase 2 study.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 501-501	2.2	0
106	TUBB4A interacts with MYH9 to protect the nucleus during cell migration and promotes prostate cancer via GSK3 β /E-catenin signalling.. <i>Nature Communications</i> , 2022 , 13, 2792	17.4	0
105	Reply from Authors re: Tracy L. Rose, Matthew I. Milowsky. A Small Step Toward Improving Salvage Treatment for Metastatic Bladder Cancer--At What Cost? <i>Eur Urol</i> 2016;69:642-44: Combination Chemotherapy as a Viable Salvage Therapy Strategy for Advanced Urothelial Carcinoma. <i>European Urology</i> , 2016 , 69, 644-645	10.2	
104	Editorial Comment. <i>Journal of Urology</i> , 2015 , 194, 329-30	2.5	
103	Reply to L.J. Eapen et al. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3228-9	2.2	
102	Reply to YiJun Shen and DingWei Ye's Letter to the Editor re: Gregory R. Pond, Andrew J. Armstrong, Brian A. Wood, et al. Evaluating the Value of Number of Cycles of Docetaxel and Prednisone in Men With Metastatic Castration-Resistant Prostate Cancer. <i>Eur Urol</i> 2012;61:363B. <i>European Urology</i> , 2012 , 61, e4-e5	10.2	
101	Emerging first line treatment options for bladder cancer: a review of phase II and III therapies in the pipeline. <i>Expert Opinion on Emerging Drugs</i> , 2017 , 22, 347-355	3.7	
100	Editorial Comment. <i>Urology</i> , 2017 , 108, 140-141	1.6	
99	Editorial comment. <i>Urology</i> , 2017 , 106, 124	1.6	
98	Words of Wisdom. Re: Androgen Deprivation Therapy plus Docetaxel and Estramustine Versus Androgen Deprivation Therapy Alone for High-risk Localised Prostate Cancer (GETUG 12): A Phase 3 Randomised Controlled Trial. <i>European Urology</i> , 2015 , 68, 1098-9	10.2	
97	Novel agents for advanced bladder cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2009 , 1, 37-50	5.4	
96	Everolimus for renal cell carcinoma: predictive factors for response and future directions. <i>Medical Oncology</i> , 2009 , 26, 46-53	3.7	
95	Reply to neoadjuvant therapy followed by prostatectomy for clinically localized prostate cancer. <i>Cancer</i> , 2008 , 112, 2519-2519	6.4	
94	Neoadjuvant therapy as a paradigm to develop systemic cancer therapy. <i>Drug Development Research</i> , 2008 , 69, 388-397	5.1	
93	Bladder cancer update. Current evaluation methods and standard of care. <i>Postgraduate Medicine</i> , 2006 , 119, 30-7	3.7	

92	Patients with unusual bladder malignancies and a rare cause of splenomegaly. Case 1. Small-cell carcinoma of the urinary bladder. <i>Journal of Clinical Oncology</i> , 2005 , 23, 4458-9	2.2
91	Ongoing Trial and Clinical Trial Endpoint Debate: The Role of Pathologic Response as a Surrogate of Survival Endpoints 2022 , 75-89	
90	Randomized trial of enzalutamide versus bicalutamide in combination with androgen deprivation in metastatic hormone sensitive prostate cancer: A Prostate Cancer Clinical Trials Consortium trial.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 190-190	2.2
89	C-reactive protein as a prognostic factor in advanced urothelial carcinoma receiving chemotherapy or immunotherapy.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 436-436	2.2
88	Comprehensive analysis of AR alterations in cell free DNA from prostate cancer patients.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 314-314	2.2
87	Delayed PSA responses in metastatic castration resistant prostate cancer (mCRPC) patients (pts) treated with sipuleucel-T.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e17041-e17041	2.2
86	Predictive role of CT texture analysis in patients with metastatic urothelial cancer treated with PD-1/PD-L1 inhibitors.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 424-424	2.2
85	Validated five-factor prognostic model for survival of patients (pts) with metastatic urothelial carcinoma (mUC) receiving different post-platinum PD-L1 inhibitors.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 476-476	2.2
84	A phase II, multicenter, single-arm trial of CV301 plus atezolizumab (Atezo) in locally advanced (unresectable) or metastatic urothelial cancer (UC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, TPS494-TPS494 ²	2.2
83	Discovery of targetable mutational signatures in advanced prostate cancer (aPC) using machine learning and next-generation sequencing (NGS) of circulating tumor DNA (ctDNA).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 226-226	2.2
82	Circulating cell-free methylated DNA (cfmeDNA) to predict postoperative recurrence in patients with muscle-invasive bladder cancer (MIBC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 454-454	2.2
81	Resource utilization and cost efficacy analysis of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (DD-MVAC) versus gemcitabine-cisplatin (GC) as neoadjuvant chemotherapy (NAC) for muscle invasive bladder cancer (MIBC).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 4022-4022	2.2
80	Impact of concurrent angiotensin inhibitors on outcomes with PD1/L1 inhibitors for patients (pts) with metastatic urothelial carcinoma (mUC).. <i>Journal of Clinical Oncology</i> , 2020 , 38, e17044-e17044	2.2
79	Detection of urothelial carcinoma using plasma cell-free methylated DNA.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 5046-5046	2.2
78	Genomic alterations associated with the progression from castration-sensitive to castration-resistant metastatic prostate cancer based on machine learning analysis of cell-free DNA genomic profile.. <i>Journal of Clinical Oncology</i> , 2020 , 38, e17596-e17596	2.2
77	Dissecting outcomes of patients (pts) with . <i>Journal of Clinical Oncology</i> , 2020 , 38, 5043-5043	2.2
76	Outcomes of patients (pts) with metastatic urothelial carcinoma (mUC) following discontinuation of enfortumab-vedotin (EV): Emergence of a new unmet need.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 5048-5048	2.2
75	Reply by Authors. <i>Journal of Urology</i> , 2020 , 203, 1155	2.5

- 74 External validation of nomogram to predict progression-free survival at 6 months (PFS6) in patients receiving salvage therapy for advanced urothelial carcinoma (UC).. *Journal of Clinical Oncology*, **2014**, 32, 4542-4542 2.2
- 73 Chemoradiation for locally advanced penile squamous cell carcinoma (PSCC): A multi-institution retrospective study.. *Journal of Clinical Oncology*, **2014**, 32, e15616-e15616 2.2
- 72 Impact of African American (AA) race on outcomes with radical cystectomy (RC) for urothelial carcinoma of the bladder (UCB).. *Journal of Clinical Oncology*, **2014**, 32, e15503-e15503 2.2
- 71 Carfilzomib for metastatic castration-resistant prostate cancer (mCRPC) following chemotherapy and androgen pathway inhibitors.. *Journal of Clinical Oncology*, **2014**, 32, TPS5101-TPS5101 2.2
- 70 Patient eligibility and trial design for the salvage therapy of advanced urothelial carcinoma (UC) based on the impact of prognostic factors.. *Journal of Clinical Oncology*, **2014**, 32, 4514-4514 2.2
- 69 Pancreatitis with vascular endothelial growth factor receptor tyrosine kinase inhibitors.. *Journal of Clinical Oncology*, **2014**, 32, e13547-e13547 2.2
- 68 Immunohistochemistry (IHC) to enhance the prognostic allocation of locally advanced and metastatic urothelial cancer (UC) undergoing first-line chemotherapy (CT).. *Journal of Clinical Oncology*, **2014**, 32, 4547-4547 2.2
- 67 Prognostic role of derived neutrophil to lymphocyte ratio (dNLR) in men with metastatic castration resistant prostate cancer (mCRPC) treated in a phase 3 trial (VENICE).. *Journal of Clinical Oncology*, **2014**, 32, 5047-5047 2.2
- 66 A phase I study of BPX-201 vaccine plus AP1903 for chemo-naive metastatic castrate-resistant prostate cancer (mCRPC).. *Journal of Clinical Oncology*, **2014**, 32, TPS3132-TPS3132 2.2
- 65 Congestive heart failure with vascular endothelial growth factor receptor tyrosine kinase inhibitors.. *Journal of Clinical Oncology*, **2014**, 32, e13502-e13502 2.2
- 64 Identification of potentially targetable kinases by concurrent high-throughput functional kinomics and RNA-sequencing (seq) of muscle-invasive bladder cancer (MIBC).. *Journal of Clinical Oncology*, **2014**, 32, 4553-4553 2.2
- 63 Impact of first-line cisplatin versus non-cisplatin based chemotherapy on progression-free survival in patients with advanced urothelial carcinoma previously treated with perioperative cisplatin based chemotherapy.. *Journal of Clinical Oncology*, **2015**, 33, 335-335 2.2
- 62 Association of changes in measurable disease by RECIST with survival in metastatic castration-resistant prostate cancer (mCRPC).. *Journal of Clinical Oncology*, **2015**, 33, 186-186 2.2
- 61 Kinase gene expression profiling of metastatic tumor tissue to prioritize therapeutic targets in clear cell renal cell carcinoma.. *Journal of Clinical Oncology*, **2015**, 33, 476-476 2.2
- 60 Association of baseline IL-8 and ferritin with clinical outcome with everolimus and BNC105P in the DisrupTOR-1 trial.. *Journal of Clinical Oncology*, **2015**, 33, 475-475 2.2
- 59 Impact of obesity in patients with metastatic urothelial carcinoma.. *Journal of Clinical Oncology*, **2015**, 33, 346-346 2.2
- 58 Safety of cisplatin in patients with urothelial carcinoma (UC) and renal dysfunction.. *Journal of Clinical Oncology*, **2015**, 33, 321-321 2.2
- 57 Externally validated improved 5-factor prognostic model in patients (pts) receiving salvage systemic therapy for advanced urothelial carcinoma (UC).. *Journal of Clinical Oncology*, **2015**, 33, 4527-4527^{2,2} 2.2

56	Validation of correlation of RECIST changes with survival in metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 5057-5057	2.2
55	Meta-analysis of the impact of single agent daily prednisone on outcomes and toxicities in metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2015 , 33, e16095-e16095	2.2
54	Gene expression profiling to improve prognostic stratification of men with advanced penile squamous cell cancer (PSCC) receiving first-line systemic therapy.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e15633-e15633	2.2
53	Sequencing of chemotherapy and androgen-axis inhibitors (AAIs) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2015 , 33, e16030-e16030	2.2
52	Fatigue with vascular endothelial growth factor receptor tyrosine kinase inhibitors and mammalian target of rapamycin inhibitors in patients with malignancies: A meta-analysis of randomized clinical trials.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e15583-e15583	2.2
51	Baseline analysis of circulating tumor cell (CTC) enumeration and androgen receptor (AR) localization in men with metastatic castration-resistant prostate cancer (mCRPC) in TAXYNERGY.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 5031-5031	2.2
50	Single agent versus doublet chemotherapy as second-line therapy of metastatic urothelial carcinoma (UC): A meta-analysis.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e15527-e15527	2.2
49	Gemcitabine and platinum (GC) chemotherapy alone or with a taxane (GC-T) as first-line therapy for urothelial cancer (UC): A meta-analysis.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e15526-e15526	2.2
48	Multi-targeted agents in the treatment of urothelial carcinoma	353-361
47	Perioperative chemotherapy for muscle-invasive urothelial carcinoma of the bladder	2015 , 142-156
46	Impact of single agent daily prednisone on survival and toxicities in post-docetaxel men with metastatic castration-resistant prostate cancer (mCRPC): An analysis of 2 phase III trials.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 213-213	2.2
45	Pan-HER tyrosine-kinase inhibitors (TKI) dacomitinib and afatinib in penile squamous cell carcinoma (PSCC): Results from an ongoing open-label, single-group, phase 2 trial of dacomitinib in chemo-naïve patients (pts).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 483-483	2.2
44	Impact of prior platinum on patients receiving salvage systemic therapy for advanced urothelial carcinoma (UC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 386-386	2.2
43	Association of a combined panel of tumor infiltrating lymphocytes, plasma cells, and macrophages with recurrence of localized clear cell (cc) renal cell carcinoma (RCC) undergoing surgery.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 502-502	2.2
42	The RISC nomogram (RN) to predict overall survival (OS) of patients (pts) with metastatic urothelial carcinoma (mUC) receiving first-line platinum-based combination chemotherapy (CT).. <i>Journal of Clinical Oncology</i> , 2016 , 34, e16026-e16026	2.2
41	Validation of the association of RECIST 1.0 changes with survival in men with metastatic castration-resistant prostate cancer (mCRPC) treated on SWOG Study S0421.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 5079-5079	2.2
40	Comprehensive analysis of five key immune related adverse events (irAE) from immune checkpoint blockers (ICB) CTLA-4 and PD-1 inhibitors in cancer patients.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3068-3068	2.2
39	Multiplatform comprehensive kinase analysis of muscle-invasive bladder cancer (MIBC) to identify potentially actionable therapeutic targets.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e16014-e16014	2.2

38	Circulating cell-free DNA profiling for potentially actionable targets in metastatic castration resistant prostate cancer (mCRPC) using next-generation sequencing on droplet volumes of plasma.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e16579-e16579	2.2
37	Statin use and survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate or enzalutamide.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e16503-e16503	2.2
36	Development and validation of a prognostic model for overall survival in chemotherapy-naive men with metastatic castration-resistant prostate cancer (mCRPC) from the phase 3 prevail clinical trial.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 5022-5022	2.2
35	Nomogram to assess survival benefit of new over historical agents as salvage therapy for metastatic urothelial carcinoma (mUC) in non-randomized trials.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e16012-e16012	2.2
34	Impact of perioperative chemotherapy and radiation for locally advanced penile squamous cell carcinoma (PSCC).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 4589-4589	2.2
33	Chemotherapy for castration-resistant prostate cancer 2011 , 80-90	
32	The preclinical activity of lenalidomide in urothelial carcinoma (UC).. <i>Journal of Clinical Oncology</i> , 2012 , 30, e15002-e15002	2.2
31	Neoadjuvant therapy preceding cytoreductive nephrectomy to develop individualized first-line therapy with everolimus for advanced renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , 2012 , 30, TPS4678-TPS4678	2.2
30	Risk of venous thromboembolism in cancer patients treated with cisplatin: A systematic review and meta-analysis.. <i>Journal of Clinical Oncology</i> , 2012 , 30, e21016-e21016	2.2
29	Clinical Management of Elderly Patients with Metastatic Prostate Cancer Chemotherapy 2013 , 179-201	
28	Progression-free survival as an endpoint for clinical trials in first-line metastatic urothelial cancer.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 251-251	2.2
27	Study of the impact of Charlson comorbidity index and hypertension on survival in patients with metastatic castration-resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 111-111	2.2
26	The preclinical anti-angiogenic and pro-apoptotic activity of lenalidomide in urothelial carcinoma (UC).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 294-294	2.2
25	CEP-11981, a small molecule inhibitor of multiple angiogenic targets, in a preclinical system of urothelial carcinoma (UC).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 293-293	2.2
24	Updated phase I results of a phase I/II trial of BNC105P with everolimus in patients with metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 397-397	2.2
23	Incidence and risk of treatment-related mortality in patients with renal cell cancer (RCC) and non-RCC treated with mammalian target of rapamycin (mTOR) inhibitors.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 347-347	2.2
22	Cisplatin-associated nephrotoxicity in clinical trials using serum creatinine (SCr) versus calculated glomerular filtration rate (GFR) as inclusion criterion: A meta-analysis.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 272-272	2.2
21	Cisplatin-based combination chemotherapy in elderly patients with metastatic urothelial cancer.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 269-269	2.2

20	Predictive and prognostic significance of early positron emission tomography/computed tomography (PET/CT) in advanced transitional cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 341-341	2.2
19	Meta-analysis of randomized trials to study the impact of prednisone on toxicities and survival in metastatic castration-resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 28-28	2.2
18	Prognostic impact of C-reactive protein (CRP) in metastatic prostate cancer (MPC): A systematic review and meta-analysis.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 43-43	2.2
17	Integrated comprehensive high-throughput kinomics profiling and whole exome sequencing of penile squamous cell cancer (PSCC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 383-383	2.2
16	Comprehensive kinase profiling to classify clear cell (cc)-renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 409-409	2.2
15	Disparities in reporting and representation of women, older adults and racial minorities in immune checkpoint inhibitor (ICI) clinical trials.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 6549-6549	2.2
14	Genetic ancestry and clinical outcomes to immune checkpoint inhibitors among seven common cancers.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 10536-10536	2.2
13	Association between tumor mutational burden (TMB) and immune-related adverse events (irAEs) in patients (pts) with metastatic urothelial carcinoma (mUC) during checkpoint immunotherapy.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 489-489	2.2
12	Impact of concurrent ACE inhibitors and ARBs on outcomes with immune-checkpoint inhibitors (ICIs) for patients (pts) with metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 354-354	2.2
11	Sequential Response to Inhibition With Subsequent Exceptional Response to Atezolizumab in a Patient With Fusion-Positive Metastatic Urothelial Carcinoma. <i>JCO Precision Oncology</i> , 2018 , 2,	3.6
10	Management of Metastatic Penile Cancer 2021 , 125-132	
9	Serial ctDNA evaluation to predict clinical progression in patients with advanced urothelial carcinoma.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 532-532	2.2
8	Initial results of a phase II study of nivolumab(N) and ipilimumab(I) in genitourinary malignancies with neuroendocrine differentiation.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 569-569	2.2
7	Impact of angiotensin-converting enzyme inhibitors (ACEi) on pathologic complete response with neoadjuvant chemotherapy (NAC) for muscle-invasive bladder cancer (MIBC).. <i>Journal of Clinical Oncology</i> , 2022 , 40, 485-485	2.2
6	Multiplexed autoantibody (AA) profiling of patients (pts) with metastatic urothelial carcinoma (mUC) receiving immune checkpoint inhibitors or platinum-based chemotherapy.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 558-558	2.2
5	PATRIOT II: An ambispective, observational, multicenter, 2-cohort study of avelumab (Ave) first-line maintenance (1LM) in locally advanced/metastatic urothelial carcinoma (la/mUC) in the United States.. <i>Journal of Clinical Oncology</i> , 2022 , 40, TPS578-TPS578	2.2
4	Phase 2 trial of CV301 vaccine plus atezolizumab (Atezo) in advanced urothelial carcinoma (aUC).. <i>Journal of Clinical Oncology</i> , 2022 , 40, 511-511	2.2
3	A systematic review and network meta-analysis evaluating neoadjuvant treatments in muscle-invasive bladder cancer.. <i>Journal of Clinical Oncology</i> , 2022 , 40, 518-518	2.2

2 FOXP3+ T-cell infiltration is associated with improved outcomes in metastatic urothelial carcinoma (mUC) treated with immune-checkpoint inhibitors (ICI).. *Journal of Clinical Oncology*, **2022**, 40, 549-549 2.2

1 Trial in progress: A phase 2, randomized, open-label study of trilaciclib with first-line, platinum-based chemotherapy and avelumab maintenance in untreated patients with locally advanced or metastatic urothelial carcinoma (PRESERVE 3).. *Journal of Clinical Oncology*, **2022**, 40, TPS585-TPS585 2.2